Halozyme Delivers Record Quarter, Raises Outlook, and Wins Wall Street Praise

Strong Q2 for Halozyme: Revenue $481M (+48% YoY), royalties +50%. Raises 2026 guidance. H.C. Wainwright, Leerink, Morgan Stanley upgrade.